Blame The Science, Not Regulation, For Targeted Therapy Shortfalls – FDA
Executive Summary
In a report both boastful and defensive in tone, the agency explains why some disease areas are rife with targeted therapies while others have few or none.
You may also be interested in...
Once More, With Statistics: FDA Defends Division Productivity Differences
Is it a problem that new drugs clear some review divisions faster than others? FDA analysis attributes differences to the proportion of applications qualifying for expedited review – a natural outgrowth of the priority placed on medical advances – not a management problem in need of a fix.
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.
FDA Responds to Nagging Questions About “Lagging” Drug Review Divisions
It’s a question FDA has heard on Capitol Hill throughout the 21st Century Cures process: Why can’t all drug review divisions keep pace with the approvals seen in the oncology office – and shouldn’t steps be taken to ease development pathways for “lagging” conditions like Alzheimer’s and rare diseases? In the face of a tougher “Cures” debate in the Senate, FDA issues a white paper to more fully outline its response.